HIV Dementia
8
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Treatment Research
10 treatments under study, led by Cognitive Stimulation Program
Research Leaders
12 sponsors active, led by University of Pennsylvania
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
12.5%
1 terminated out of 8 trials
80.0%
-6.6% vs benchmark
38%
3 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (8)
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange
Exploring Racial Disparities in Sleep Health and Neurocognitive Function
Intranasal Insulin for the Treatment of HAND
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders
A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
Research Network
Common Treatments
- Cognitive Stimulation Program1
- Sv2a Pet1
- Insulin Intranasal1
- Tspo Pet1
- Placebo Intranasal1
Active Sponsors
- University of Pennsylvania2
- National Institutes of Health (NIH)1
- University of Alabama, Tuscaloosa1
- Yale University1
- National Institute of Allergy and Infectious Diseases (NIAID)1
Top Investigators
University of Pennsylvania
The University of Alabama
Universidad Nacional Autonoma de Mexico
UCLA Center for AIDS Research and Educationi
Universidad Nacional Autonoma de Mexico
Related Conditions
- Healthy1
- Hiv Encephalitis1
- Hivassociated Cognitive Motor Complex1
- Neuropsychology1
- Telerehabilitation1